BridgeBio Pharma's major customers
Bayer accounted for 14% of BridgeBio Pharma's revenue in FY 2025, down from 59% a year earlier.
Get an email when BridgeBio Pharma's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of BridgeBio Pharma
Customers that BridgeBio Pharma named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Bayer | 14% | ▼ from 59% | 2 years | FY 2025 · filed 24 Feb 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Bristol Myers SquibbBMY | 81% | last FY 2023 | 2 years | FY 2023 · filed 24 Feb 2026 |
| Bayer Consumer Care | 59% | last FY 2024 | 1 year | FY 2024 · filed 20 Feb 2025 |
| Kyowa Kirin | 34% | last FY 2024 | 1 year | FY 2024 · filed 20 Feb 2025 |
| Kyowa Kirin Co.Ltd | 34% | last FY 2024 | 1 year | FY 2024 · filed 24 Feb 2026 |
| Lian BioLIANY | 14% | last FY 2023 | 1 year | FY 2023 · filed 24 Feb 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API